U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07283705) titled 'A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer' on Dec. 11.
Brief Summary: To find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Cohorts 2 and 3) can help to control pancreatic cancer.
Study Start Date: May 18, 2026
Study Type: INTERVENTIONAL
Condition:
Phase 2 Study
BMS-986504
MTAP-deleted Pancreatic Cancer
Intervention:
DRUG: BMS-986504
Given by po
DRUG: Gemcitabine
Given by IV
DRUG: Nab-paclitaxel
Given by IV
DRUG: mFOLFIRINOX
Given by iv
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M....